HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization.

Abstract
Oncogenic transcription factors lacking enzymatic activity or targetable binding pockets are typically considered "undruggable". An example is provided by the EWS-FLI1 oncoprotein, whose continuous expression and activity as transcription factor are critically required for Ewing sarcoma tumor formation, maintenance, and proliferation. Because neither upstream nor downstream targets have so far disabled its oncogenic potential, we performed a high-throughput drug screen (HTS), enriched for FDA-approved drugs, coupled to a Global Protein Stability (GPS) approach to identify novel compounds capable to destabilize EWS-FLI1 protein by enhancing its degradation through the ubiquitin-proteasome system. The protein stability screen revealed the dual histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) inhibitor called fimepinostat (CUDC-907) as top candidate to modulate EWS-FLI1 stability. Fimepinostat strongly reduced EWS-FLI1 protein abundance, reduced viability of several Ewing sarcoma cell lines and PDX-derived primary cells and delayed tumor growth in a xenograft mouse model, whereas it did not significantly affect healthy cells. Mechanistically, we demonstrated that EWS-FLI1 protein levels were mainly regulated by fimepinostat's HDAC activity. Our study demonstrates that HTS combined to GPS is a reliable approach to identify drug candidates able to modulate stability of EWS-FLI1 and lays new ground for the development of novel therapeutic strategies aimed to reduce Ewing sarcoma tumor progression.
AuthorsGloria Pedot, Joana Graça Marques, Philip P Ambühl, Marco Wachtel, Stephanie Kasper, Quy A Ngo, Felix K Niggli, Beat W Schäfer
JournalNeoplasia (New York, N.Y.) (Neoplasia) Vol. 27 Pg. 100784 (05 2022) ISSN: 1476-5586 [Electronic] United States
PMID35366465 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Retracted Publication)
CopyrightCopyright © 2022. Published by Elsevier Inc.
Chemical References
  • EWS-FLI fusion protein
  • Histone Deacetylase Inhibitors
  • Oncogene Proteins, Fusion
  • Proto-Oncogene Protein c-fli-1
  • RNA-Binding Protein EWS
  • Histone Deacetylases
Topics
  • Animals
  • Cell Line, Tumor
  • Gene Expression Regulation, Neoplastic
  • Histone Deacetylase Inhibitors (pharmacology)
  • Histone Deacetylases (genetics, metabolism)
  • Humans
  • Mice
  • Oncogene Proteins, Fusion (genetics, metabolism)
  • Proto-Oncogene Protein c-fli-1 (genetics, metabolism)
  • RNA-Binding Protein EWS (genetics, metabolism)
  • Sarcoma, Ewing (drug therapy, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: